Compounds > thioridazine-5-sulfoxide
Page last updated: 2024-09-22

thioridazine-5-sulfoxide

Description

thioridazine-5-sulfoxide: metabolite of thioridazine; cardiotoxic; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24494
CHEMBL ID3544852
MeSH IDM0122148

Synonyms (21)

Synonym
10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-, 5-oxide
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine 5-oxide
thioridazine 5-oxide
thioridazine sulfoxide
yi69b9mw63 ,
unii-yi69b9mw63
7776-05-8
thioridazine-5-oxide
thioridazine-5-sulfoxide
FT-0675191
thioridazine 5-sulfoxide
thioridazine hydrochloride impurity c [ep impurity]
thioridazine sulphoxide
10-(2-(1-methylpiperidin-2-yl)ethyl)-2-methylsulfanylphenothiazine 5-oxide
thioridazine impurity c [ep impurity]
CHEMBL3544852
10-[2-[(2rs)-1-methylpiperidin-2-yl]ethyl]-2-(methylsulfanyl)-10h-phenothiazine 5-oxide (thioridazine 5-sulfoxide)
Q27294535
DTXSID80998951
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-5lambda~4~-phenothiazin-5(10h)-one
thioridazine 5-sulfoxide(mixture of diastereomers)

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
thioridazine[no description available]medium131phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
mesoridazine[no description available]medium41phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
2-methylpentane[no description available]medium10alkane
ether[no description available]medium10ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
diethylamine[no description available]medium10secondary aliphatic amine
methanol[no description available]medium10alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
carbamates[no description available]medium10amino-acid anion
quinidine[no description available]medium10cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
mephenytoin[no description available]medium11imidazolidine-2,4-dioneanticonvulsant
sulforidazine[no description available]medium31phenothiazines
dextromethorphan[no description available]medium116-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
diphenhydramine hydrochloride[no description available]medium11hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
phenobarbital[no description available]medium10barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
ConditionIndicatedRelationship StrengthStudiesTrials
Behavior Disorders0low10
Depression, Endogenous0medium11
Depression, Neurotic0medium11
Depression, Unipolar0medium11
Depressive Disorder0medium11
Depressive Syndrome0medium11
Diagnosis, Psychiatric0low10
Melancholia0medium11
Mental Disorders0low10
Mental Disorders, Severe0low10
Mental Illness0low10
Neurosis, Depressive0medium11
Psychiatric Diagnosis0low10
Psychiatric Diseases0low10
Psychiatric Disorders0low10
Psychiatric Illness0low10
Tachyarrhythmia0low10
Tachycardia0low10
Unipolar Depression0medium11

Research Highlights

Safety/Toxicity (2)

ArticleYear
Thioridazine-5-sulfoxide cardiotoxicity in the isolated, perfused rat heart.
Toxicology letters, Volume: 21, Issue: 1		1984
Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart.
Toxicology and applied pharmacology, Volume: 86, Issue: 1		1986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

ArticleYear
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (2)

ArticleYear
Chromatographic separation of thioridazine sulphoxide and N-oxide diastereoisomers: identification as metabolites in the rat.
The Journal of pharmacy and pharmacology, Volume: 38, Issue: 7		1986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]